Sánchez J, Bartlett A, Costa A, Estruch J, Estiarte R, Soucheiron C
Department Clinical Research, Laboratorios Dr. Esteve, SA Barcelona, Spain.
Eur J Rheumatol Inflamm. 1991;11(4):50-8.
This study analyses the results of 8 randomized, controlled clinical trials and one open study carried out with droxicam (a new NSAID, pro-drug of piroxicam), comparing the adverse events and gastrointestinal tolerance of this compound against those of the control drugs used in these trials. The frequency of adverse events was lower in the droxicam treated patients. Adverse events concerning the gastrointestinal area were also lower. No differences were found in the distribution of adverse events by age of sex among the drugs compared. The pattern of side effects found was that expected in all non-steroidal anti-inflammatory agents. These results seem to sustain the hypothesis of a better tolerance of droxicam than that of piroxicam, indomethacin or diclofenac, especially in the gastrointestinal area.
本研究分析了8项随机对照临床试验以及一项使用屈昔康（一种新的非甾体抗炎药，吡罗昔康的前体药物）开展的开放性研究的结果，比较了该化合物与这些试验中使用的对照药物的不良事件及胃肠道耐受性。接受屈昔康治疗的患者不良事件发生率较低。涉及胃肠道方面的不良事件也较少。在所比较的药物中，未发现不良事件按年龄和性别分布存在差异。所发现的副作用模式与所有非甾体抗炎药预期的一致。这些结果似乎支持以下假设：屈昔康的耐受性优于吡罗昔康、吲哚美辛或双氯芬酸，尤其是在胃肠道方面。
